ISPOR 2021

Virtual

May 17 - May 20, 2021

Virtual |

 

ISPOR pic.png
HEOR: Evolving for Tomorrow’s Challenges

2020 has forced many professions, research fields, and industries to an inflection point, requiring verification of direction and opportunities to chart a new roadmap for development. Healthcare systems’ resilience and sustainability is being tested to its maximum, challenging prepandemic priorities under unprecedented resource constraints. This has highlighted opportunities and challenges in HEOR methods, practices, and application including our ability to respond effectively. 

Parexel presentation

Virtual Poster Discuss Session 3  - Wednesday, May 19 
Viewing: 11:30 am - 1:45 pm
Methodological & Statistical Research

PIN68: Estimating Effects in Observational Real-World Data, From Target Trials to Targeted Learning- Example of Treating COVID-Hospitalized Patients
Authors:
Paula Chakravarti, Epidemiology Director
Andy Wilson, Scientific Lead
Sergey Krikov, Scientific Data Technology Director
Nan Shao, CVP, Head of Global Analytics Strategy
M. van der Laan, University of California Berkeley, Berkeley

Other sessions include:

Indication-based pricing – a necessary side effect of the COVID-19 pandemic?
Project Orbis and the Access Consortium - are quicker regulatory approvals leading to faster access?
Cost-Effectiveness of Nivolumab for the Treatment of Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy: A United-States Payer Perspective
A cost-effectiveness analysis of nivolumab plus ipilimumab plus 2 cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy in the first-line treatment of stage IV or recurrent non-small cell lung cancer in Canada
A cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum doublet chemotherapy versus platinum doublet chemotherapy in the first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States
What Is the IMPACT of the Introduction of Ipilimumab, Pembrolizumab, and Nivolumab on
Malignant Melanoma in Nordics?
Comparative Effectiveness Of Docetaxel And Paclitaxel In Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant To Previous Chemotherapy: Propensity Score-Matching Analyses From Attraction-3 Trial

 

EVENT WEBSITE

We are always available for a conversation.

*  

We are always available for a conversation.

Submitting...

Communication Preference

Communication Preference